FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marc Maliepaard

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Tumor Cells, Cultured

Concepts & Ideas

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Marc Maliepaard; Charity Nofziger; Michael Pacanowski; Marisa Papaluca; Silvia Dossena; Falk Ehmann; Christian Grimstein; Krishna Prasad; Yoshiaki Uyama; Issam Zineh; Markus Paulmichl
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
Marc Maliepaard; Steven Teerenstra; Nikola Banishki; Christine C Gispen-de Wied; André J Elferink
Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin.
Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Requirements for generic anti-epileptic medicines: a regulatory perspective.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marc Maliepaard (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marc Maliepaard; Charity Nofziger; Michael Pacanowski; Marisa Papaluca; Silvia Dossena; Falk Ehmann; Christian Grimstein; Krishna Prasad; Yoshiaki Uyama; Issam Zineh; Markus Paulmichl
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective.
Nature reviews. Drug discovery 2013;12(2):103-15.
2011: Marc Maliepaard; Steven Teerenstra; Nikola Banishki; Christine C Gispen-de Wied; André J Elferink
Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin.
European journal of clinical pharmacology 2011;67(10):1007-16.
2009: Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Requirements for generic anti-epileptic medicines: a regulatory perspective.
Journal of neurology 2009;256(12):1966-71.
2003: Mirjam Crul; Nadja E Schoemaker; Dick Pluim; Marc Maliepaard; René W M Underberg; Margaret Schot; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3526-33.
2003: J H M Schellens; A S T Planting; nico van zandwijk; J Ma; Marc Maliepaard; M E L van der Burg; MM de Boer-Dennert; E Brouwer; Ate van der Gaast; Martin J van den Bent; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
British journal of cancer 2003;88(6):814-21.
2002: Julio E Diestra; George L Scheffer; Isabel Català; Marc Maliepaard; Jan H M Schellens; Rik J Scheper; Josep Ramón Germà-Lluch; Miguel A Izquierdo
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
The Journal of pathology 2002;198(2):213-9.
2002: Annemarie H Van Hattum; I J Hoogsteen; Hennie M M Schlüper; Marc Maliepaard; George L Scheffer; Rik J Scheper; G Kohlhagen; Y Pommier; HERBERT PINEDO; Epie Boven
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
British journal of cancer 2002;87(6):665-72.
2002: Ian F Faneyte; Petra M P Kristel; Marc Maliepaard; George L Scheffer; Rik J Scheper; Jan H M Schellens; Marc J van de Vijver
Expression of the breast cancer resistance protein in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1068-74.
2002: Jetske M Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M Tibben; Albert Huisman; Wim W ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E Voest; Jos H Beijnen; Jan M Schellens
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2001: J H M Schellens; A S T Planting; J Ma; Marc Maliepaard; A de Vos; MM de Boer-Dennert; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
Anti-cancer drugs 2001;12(8):667-75.
2001: Marc Maliepaard; George L Scheffer; Ian F Faneyte; Margôt van Gastelen; Adriana C L M Pijnenborg; Alfred H Schinkel; Marc J van de Vijver; Rik J Scheper; J H M Schellens
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Cancer research 2001;61(8):3458-64.
2001: Marc Maliepaard; Margôt van Gastelen; A Tohgo; FREDERICK HAUSHEER; Robert C A M van Waardenburg; Laurina A de Jong; Dick Pluim; Jos H Beijnen; J H M Schellens
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
2001: Charles Erlichman; Scott A Boerner; C G Hallgren; R Spieker; X Y Wang; C David James; George L Scheffer; Marc Maliepaard; Douglas Ross; Keith C Bible; Scott H Kaufmann
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Cancer research 2001;61(2):739-48.
2000: johan jonker; Johan W Smit; Remco F Brinkhuis; Marc Maliepaard; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Journal of the National Cancer Institute 2000;92(20):1651-6.
2000: George L Scheffer; Marc Maliepaard; Adriana C L M Pijnenborg; Margôt van Gastelen; Mariska C de Jong; Anouk B Schroeijers; Dorina M van der Kolk; J D Allen; Douglas Ross; Paul Van Der Valk; W S Dalton; J H M Schellens; Rik J Scheper
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Cancer research 2000;60(10):2589-93.
2000: J H M Schellens; Marc Maliepaard; Rik J Scheper; George L Scheffer; johan jonker; Johan W Smit; Jos H Beijnen; Alfred H Schinkel
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Annals of the New York Academy of Sciences 2000;922():188-94.
1999: Dick Pluim; Marc Maliepaard; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: Marc Maliepaard; Margôt van Gastelen; Laurina A de Jong; Dick Pluim; Robert C A M van Waardenburg; M C Ruevekamp-Helmers; BG Floot; J H M Schellens
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer research 1999;59(18):4559-63.
1999: M de Graaff; Marc Maliepaard; Dick Pluim; B J Floot; Ineke Slaper-Cortenbach; J H M Schellens
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Anti-cancer drugs 1999;10(2):213-8.
1997: Mirjam Crul; J H M Schellens; Jos H Beijnen; Marc Maliepaard
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.